# Chemical and Biological Defense Program - Dem/Val — Program Element 0603884BP

**Program element:** 0603884BP  
**Component:** Defense-Wide  
**Appropriation:** 0400 — RDT&E, Defense-Wide  
**Budget Activity:** 4 — Advanced Component Development & Prototypes  
**Vintage:** President's Budget PB2027  
**Canonical URL:** https://hitchintel.com/programs/0603884BP

## Summary

Defense-Wide funding ramps 46% to a $391.3M request in FY2027 — the program's peak. In the FY2027 defense authorization, the House funded it in full; the Senate funded it in full; House appropriators added 1.3% (to $396.3M). IDBiologics leads the industry work, though an unusually large share flows to government labs and warfare centers.

## Funding profile

| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 283.7 |
| FY2026 | Enacted | 267.2 |
| FY2027 | Request | 391.3 |
| FY2028 | Outyear | 368.4 |
| FY2029 | Outyear | 374.1 |
| FY2030 | Outyear | 364.2 |
| FY2031 | Outyear | 339.3 |

> Estimate types are not summed — the profile mixes actuals, enacted law, the request, and outyear projections.

## Congressional marks (FY2027)

| Stage | Marked ($M) | Change ($M) |
|---|---|---|
| Request | 391.3 | — |
| House NDAA (HASC) | 391.3 | +0.0 |
| Senate NDAA (SASC) | 391.3 | +0.0 |
| House Approps (HAC-D) | 396.3 | +5.0 |

> FY2027 NDAA authorization marks, as of 2026-07-27. Not appropriations or final law.

## Projects (4)

| Project | Title | FY2025 actual | FY2026 enacted | FY2027 request | Move |
|---|---|---|---|---|---|
| EN4 | Enabling Investments (ACD&P) | 27.6 | 20.4 | 155.4 | +663% |
| PT4 | Protect (ACD&P) | 170.6 | 158.0 | 129.2 | −18% |
| MT4 | Mitigate (ACD&P) | 33.6 | 26.8 | 55.3 | +106% |
| UN4 | Understand (ACD&P) | 51.9 | 62.0 | 51.3 | −17% |

> Projects are the summable leaves: the program element total is their sum, never added to it.

### Project EN4 — Enabling Investments (ACD&P)

The Enabling Investments Advanced Component Development and Prototypes (ACD&P) Project maintains the Department of War (DoW) advanced development manufacturing facility to rapidly develop, manufacture, and approve medical countermeasures. Enabling efforts in this area support dedicated infrastructure capabilities, demonstrations, and overarching development support functions as portfolio enablers responding to emerging threats. Priority access to the facility provides an on demand manufacturing capability not only for the DoW but for the entire United States Government enterprise. Efforts included in this Project are: (1) Chemical Biological Radiological Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC) (2) Chemical Biological Incident Preparedness and Response - Model Development (CBIPR-MODEL) - Non-Clinical Testing (3) CBIPR-MODEL - Alternative non-clinical model development and evaluation (4) Chemical Biological Radiological Nuclear Defense Experimentation (CBRNDEX) - Integrated CBDP Experimentation (5) Chemical Biological Radiological and Nuclear Defense Forward Element Experimentation and Prototyping (CBRND FE EXPP) (6) Forge High Performance Computing (FHPC) (7) Integrated Early Warning Manufacturing Optimization (IEW MFRO) (8) Medical Countermeasures Manufacturing Optimization (MCM MFRO) - Biological and chemical manufacturing platforms (9) Medical Countermeasures Manufacturing Optimization (MCM MFRO) - Small Molecule Synthesis (10) Rapid Response Sprint Advanced Development (RRS ADV) (11) Congressional Continuous Antibody Manufacturing Twin (CONG CAMT)

**Named R-3 performers** (share of this project's FY2027 R-3 total, so they need not reach 100%)**:** Just – Evotec Biologics (8.1, 5.2%).

| Activity (R-2A) | FY2025 | FY2026 | FY2027 |
|---|---|---|---|
| 1) CBRN Advance Defense Enabling Network and Clinical Capability (CADENCC) | — | — | 9.5 |
| 2) Chemical Biological Incident Preparedness and Response - Model Development (CBIPR-MODEL) - Non-Clinical Testing | 4.4 | 4.9 | 4.6 |
| 3) Chemical Biological Incident Preparedness and Response - Model Development (CBIPR-MODEL) - Alternative non-clinical model development and evaluation | — | — | 9.4 |
| 4) Chemical Biological Radiological Nuclear Defense Experimentation (CBRNDEX) - Integrated CBDP Experimentation | — | — | 9.6 |
| 5) Chemical Biological Radiological and Nuclear Defense Forward Element Experimentation and Prototyping (CBRND FE EXPP) | — | — | 9.8 |
| 6) Forge High Performance Computing (FHPC) | — | — | 85.0 |
| 7) Integrated Early Warning Manufacturing Optimization (IEW MFRO) | — | — | 14.2 |
| 8) Medical Countermeasures Manufacturing Optimization (MCM MFRO) - Biological and chemical manufacturing platforms | 19.2 | 8.1 | 8.5 |
| 9) Medical Countermeasures Manufacturing Optimization (MCM MFRO) - Small Molecule Synthesis | 4.0 | 3.5 | 3.7 |
| 10) Rapid Response Sprint Advanced Development (RRS ADV) | — | — | 1.1 |

> R-2A activities carry the prior, current and budget year only — no five-year plan. Coverage is partial, so count them, never total them.

### Project PT4 — Protect (ACD&P)

The Protect Advanced Component Development and Prototypes (ACD&P) Project provides the ability to shield the Joint Force from harm caused by chemical and biological (CB) hazards by preventing or reducing individual and collective exposures, applying prophylaxis to prevent or mitigate negative physiological effects, and protecting critical equipment. Efforts included in this Project are: (1) Accelerated Antibodies - Enhanced Biological Defense (AA-ENBD) (2) Biological Containment Isolation System - Enhanced Biological Defense (BCIS-ENBD) (3) Generative Unconstrained Intelligent Drug Engineering-Enhanced Biological Defense (GUIDE-ENBD) (4) Medical Countermeasures Platform Technologies (MCMPT) - Prevention Platform (5) MCMPT - Host Directed Countermeasure (6) Plague Monoclonal Antibodies (PLG MAB) (7) Prophylactic Technology Systems (ProTecS) (8) Vaccine Acceleration by Modular Progression - Enhanced Biological Defense (VAMP-ENBD) (9) Portable Patient Transport System - Enhanced Biological Defense (PPTS-ENBD) (10) Shipboard Isolation System (SIS)

**Named R-3 performers** (share of this project's FY2027 R-3 total, so they need not reach 100%)**:** IDBiologics (22.0, 17%), Autonomous Therapeutics (8.4, 6.5%), Battelle Memorial Institute (7.5, 5.8%), Just – Evotec Biologics (7.0, 5.4%).

| Activity (R-2A) | FY2025 | FY2026 | FY2027 |
|---|---|---|---|
| 1) Accelerated Antibodies - Enhanced Biological Defense (AA-ENBD) | 39.4 | 26.9 | 32.1 |
| 2) Biological Containment Isolation System - Enhanced Biological Defense (BCIS-ENBD) | 1.1 | 0.4 | — |
| 3) Generative Unconstrained Intelligent Drug Engineering - Enhanced Biological Defense (GUIDE-ENBD) | 61.8 | 60.8 | 45.5 |
| 4) Medical Countermeasures Platform Technologies (MCMPT) - Prevention Platform | 2.8 | 3.1 | 3.8 |
| 5) Medical Countermeasures Platform Technologies (MCMPT) - Host Directed Countermeasure | 7.9 | 7.5 | 9.0 |
| 6) Plague Monoclonal Antibodies (PLG MAB) | 6.1 | 6.0 | 0.5 |
| 7) Prophylactic Technology Systems (ProTecS) | — | — | 7.3 |
| 8) Vaccine Acceleration By Modular Progression - Enhanced Biological Defense (VAMP-ENBD) | 50.2 | 53.3 | 31.1 |
| 9) Portable Patient Transport System - Enhanced Biological Defense (PPTS-ENBD) | 0.8 | — | — |
| 10) Shipboard Isolation System (SIS) | 0.5 | — | — |

> R-2A activities carry the prior, current and budget year only — no five-year plan. Coverage is partial, so count them, never total them.

### Project MT4 — Mitigate (ACD&P)

The Mitigate Advanced Component Development and Prototypes (ACD&P) Project provides the Joint Force the ability to conduct decontamination and medical actions that enable the quick restoration of combat power; maintain/recover essential functions that are free from the effects of chemical and biological (CB) hazards; and facilitate the return to pre-incident operational capability as soon as possible. Efforts included in this Project are: (1) Autonomous Decontamination System (ADS) - Prototype Development (2) Agent-Directed Therapeutics (AD TX) - Clinical (3) Broadening Enabling Acquisition of Chemical Operational Needs (BEACON) (4) Host-Directed Therapeutics (HD TX) - Evaluation of Host Directed Candidates/Non Clinical Studies (5) Reactivating Nerve Agent Treatment System (RNATS) (6) Anti-Viral Oral Therapeutics (AVO TX) - Development Test and Evaluation (7) Botulinum Toxin Therapeutic (BOT TX) - Non-clinical Studies

**Named R-3 performers** (share of this project's FY2027 R-3 total, so they need not reach 100%)**:** JPM CBRN Medical, CPE CBRND (1.0, 1.8%).

| Activity (R-2A) | FY2025 | FY2026 | FY2027 |
|---|---|---|---|
| 1) Autonomous Decontamination System (ADS) - Prototype Development | 3.0 | 7.5 | 10.0 |
| 2) Agent-Directed Therapeutics (AD TX) - Clinical | 5.3 | 13.2 | 19.7 |
| 3) Broadening Enabling Acquisition of Chemical Operational Needs (BEACON) | — | — | 18.3 |
| 4) Host-Directed Therapeutics (HD TX) - Evaluation of Host Directed Candidates/MDD/Non Clinical Studies | — | — | 7.3 |
| 5) Reactivating Nerve Agent Treatment System (RNATS) | 9.0 | 6.2 | — |
| 6) Anti-Viral Oral Therapeutics (AVO TX) - Model Development Studies | 11.9 | — | — |
| 7) Botulinum Toxin Therapeutic (BOT TX) - Non-clinical Studies | 4.4 | — | — |

> R-2A activities carry the prior, current and budget year only — no five-year plan. Coverage is partial, so count them, never total them.

### Project UN4 — Understand (ACD&P)

The Understand Advanced Component Development and Prototypes (ACD&P) Project provides the Joint Force the ability to continually receive information about the chemical and biological (CB) situation at a desired time and place by detecting, identifying, and quantifying CB hazards in air, water, or on land, and on personnel, equipment or facilities. Efforts also develop a clear understanding of the current and predicted CB situation; collect, query, and assimilate information from sensors in real time to inform decisions and provide impacts of CB hazards. Efforts included in this Project are: (1) Advanced Differential Diagnostics (ADD) (2) Advanced Emerging Threat Defense (AET DEFENSE) (3) Colorimetric Indicator (CIND) (4) Chemical Biological Radiological Nuclear Support to Command and Control (CSC2) (5) Far Forward Biological Sequencing (FFBS) - Increment 2 (6) Genomic Enabled Sequencing (GENOMES) (7) Multi Phase Chemical Sampling and Analysis (MPCSA) (8) Surveillance and Pathogen Characterization-Enhanced Biological Defense (SPCHAR-ENBD) (9) Physiological Monitoring Sensor Suite (PM2S) (10) Chemical and Biological Wearables (CB WEARABLES) (11) Non-Targeted Sequencing Identification System (NSIS) (12) Congressional Ultra-Compact Hyperspectral Imaging Chemical Detector (CONG UCHI CD)

**Named R-3 performers** (share of this project's FY2027 R-3 total, so they need not reach 100%)**:** Capability Program Executive Chemical, B (2.1, 4.0%), DCS Corps (1.5, 2.9%).

| Activity (R-2A) | FY2025 | FY2026 | FY2027 |
|---|---|---|---|
| 1) Advanced Differential Diagnostics (ADD) | 9.4 | 15.3 | 0.7 |
| 2) Advanced and Emerging Threat Defense (AET DEFENSE) | 7.1 | 7.2 | 8.0 |
| 3) Colorimetric Indicator (CIND) | 1.6 | 2.0 | 3.7 |
| 4) Chemical Biological Radiological Nuclear Support to Command and Control (CSC2) | 25.5 | 26.5 | 28.9 |
| 5) Far Forward Biological Sequencing (FFBS) - Increment 2 | — | 3.3 | 5.8 |
| 6) Genomic Enabled Sequencing (GENOMES) | — | — | 2.4 |
| 7) Multi Phase Chemical Sampling and Analysis (MPCSA) | — | — | 0.3 |
| 8) Surveillance and Pathogen Characterization - Enhanced Biological Defense (SPCHAR-ENBD) | 1.6 | 1.7 | 1.7 |
| 9) Physiological Monitoring Sensor Suite (PM2S) | 5.0 | — | — |
| 10) Chemical and Biological Wearables (CB WEARABLES) | — | 3.2 | — |
| 11) Non-targeted Sequencing Identification System (NSIS) | 1.7 | — | — |

> R-2A activities carry the prior, current and budget year only — no five-year plan. Coverage is partial, so count them, never total them.

## Where the FY2027 request goes

| Category | Share | $M |
|---|---|---|
| Industry primes | 15% | 60.1 |
| Government labs & warfare centers | 33% | 130.5 |
| Other / unspecified | 51% | 200.7 |

**Top named industry performers:** IDBiologics ($22.0M, 5.6%), Just – Evotec Biologics ($15.1M, 3.9%), Autonomous Therapeutics ($8.4M, 2.1%).

> R-3 exhibit contract funding, not USAspending obligations.

## Mission & acquisition strategy

This program element (PE) resources Advanced Component Development and Prototypes across the Understand, Protect, Mitigate, and Enabling Investments portfolios. Program efforts validate high-risk/high-payoff technologies and their respective concepts of operations for significant improvement to warfighter capabilities in preparation for the transition of mature technologies to advanced development programs requiring chemical and biological (CB) defense technologies.

Advanced Differential Diagnostics (ADD) The Advanced Differential Diagnostics (ADD) program will utilize Other Transaction Authority (OTA) project agreements to identify, competitively prototype, and mature commercial solutions deemed technologically viable, and evaluate them in as realistic an operational environment as possible. Successful candidate systems will transition to the Engineering and Manufacturing Development phase to be further developed under the OTA agreement, in order to satisfy military and U.S. Food & Drug Administration (FDA) regulatory requirements for subsequent production and fielding to the services. Upon FDA clearance of the first ADD capability the ADD program will seek a Milestone (MS) C decision.

## Related program elements

- [0604384BP — Chemical and Biological Defense Program - EMD](https://hitchintel.com/programs/0604384BP) (Defense-Wide)
- [0604134A — Counter Improvised-Threat Demonstration, Prototype Development, and Testing](https://hitchintel.com/programs/0604134A) (Army)
- [0604746A — Automatic Test Equipment Development](https://hitchintel.com/programs/0604746A) (Army)
- [0602384BP — Chemical and Biological Defense Program](https://hitchintel.com/programs/0602384BP) (Defense-Wide)

## Source & machine access

- **Source:** FY2027 Office of the Secretary of Defense RDT&E Budget Justification, Exhibits R-2/R-3, PE 0603884BP (PB PB2027); FY2027 NDAA committee marks (as of 2026-07-27).
- **MCP:** `mcp.hitchintel.com` — `budget_get_program_element(pe="0603884BP")`.

*HitchAI is an independent intelligence service, not affiliated with the U.S. Department of Defense. Budget figures are requests/estimates, not obligations.*